Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Gemcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 2/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.91 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.91 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.56 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.56 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.46 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CDA | P32320 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gemcitabine SCHEMBL17978348 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL348218 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL350020 | 1.00 | PDE3A (0.91) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL28334969 | 0.99 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL19137411 | 0.97 | PDE3A (0.85) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL3975223 | 0.97 | PDE3A (0.89) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6761683 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL6369622 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL20827751 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA | |
| Gemcitabine SCHEMBL12737233 | 0.95 | PDE3A (1.00) | PDE3APDE4DSLC29A1POLA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | KARLSRUHER INSTITUT FUER TECH KOERPERSCHAFT DES OEFFENTLICHEN RECHTS (DE) | 2026-02-19 | — | — | US | claimed |
| US-20250025426-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2025-01-23 | — | — | US | claimed |
| CN-118986933-A | Nanometer preparation for delivering medicine on demand aiming at inherent barrier of pancreatic cancer, and preparation method and application thereof | 复旦大学 | 2024-11-22 | — | — | CN | claimed |
| EP-4444275-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2024-10-16 | — | — | EP | claimed |
| US-20240042045-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-02-08 | — | — | US | claimed |
| US-11845938-B2 | Aptamer compositions and the use thereof | CITY OF HOPE (US) | 2023-12-19 | — | — | US | claimed |
| WO-2023104380-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-15 | — | — | WO | claimed |
| CN-116249525-A | Nanoparticles containing multiple cleavable prodrugs for cancer therapy | 芝加哥大学 | 2023-06-09 | — | — | CN | claimed |
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | claimed |
| EP-4188361-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | The University of Chicago (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2017125413-A1 | MESOPOROUS ORGANOSILICA NANOPARTICLES, PRODUCTION METHOD THEREOF AND USES OF SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-07-27 | — | — | WO | claimed |
| WO-2017127697-A1 | ENCAPSULATION AND HIGH LOADING EFFICIENCY OF PHOSPHORYLATED DRUG AND IMAGING AGENTS IN NANOPARTICLES | THE PENN STATE RESEARCH FOUNDATION (US) | 2017-07-27 | — | — | WO | claimed |
| US-20160271072-A1 | POLYMER NANOPARTICLES CONTAINING MULTIPLE AGENTS AND METHODS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-09-22 | — | — | US | claimed |
| EP-3060201-A1 | POLYMER NANOPARTICLES CONTAINING MULTIPLE AGENTS AND METHODS THEREOF | The University of North Carolina At Chapel Hill (US) | 2016-08-31 | — | — | EP | claimed |
| US-20150246137-A1 | LIPID COATED NANOPARTICLES CONTAINING AGENTS HAVING LOW AQUEOUS AND LIPID SOLUBILITIES AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-03 | — | — | US | claimed |
| US-20150182634-A1 | Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action | MISSISSIPPI STATE UNIVERSITY | 2015-07-02 | — | — | US | claimed |
| WO-2015061468-A1 | POLYMER NANOPARTICLES CONTAINING MULTIPLE AGENTS AND METHODS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-04-30 | — | — | WO | claimed |
| US-20120201872-A1 | LIPOSOMES COMPRISING A CALCIUM PHOSPHATE-CONTAINING PRECIPITATE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-08-09 | — | — | US | claimed |
| EP-2428201-A1 | Oral administration of nucleoside monophosphates | Merck Serono S.A. (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2011017297-A2 | BIODEGRADABLE DELIVERY SYSTEM COMPLEXES FOR THE DELIVERY OF BIOACTIVE COMPOUNDS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201872-A1 | LIPOSOMES COMPRISING A CALCIUM PHOSPHATE-CONTAINING PRECIPITATE | LIPA, PLA2G2C, CHERP | POLA1 4735/4885PDE3A 2247/4885PDE4D 2735/4885 |
| US-20260048152-A1 | GEMCITABINE INORGANIC-ORGANIC HYBRID NANOPARTICLES | GOT1, RNMT, GNAO1 | POLA1 102/4885PDE3A 936/4885PDE4D 1933/4885 |
| US-20150246137-A1 | LIPID COATED NANOPARTICLES CONTAINING AGENTS HAVING LOW AQUEOUS AND LIPID SOLUBILITIES AND METHODS THEREOF | LIPA, LIPC, LIPG | POLA1 4461/4885PDE3A 1892/4885PDE4D 3143/4885 |
| US-11845938-B2 | Aptamer compositions and the use thereof | RNGTT, PABPC4, DNTT | POLA1 1094/4885PDE3A 2635/4885PDE4D 2094/4885 |
| US-20240042045-A1 | NANOPARTICLES CONTAINING MULTIPLE CLEAVABLE PRODUGS FOR CANCER THERAPY | LDLR, LRP6, LIPG | POLA1 1285/4885PDE3A 4186/4885PDE4D 4691/4885 |
| US-20160271072-A1 | POLYMER NANOPARTICLES CONTAINING MULTIPLE AGENTS AND METHODS THEREOF | LIPA, NPC1, PHOSPHO1 | POLA1 2959/4885PDE3A 3321/4885PDE4D 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.